



## Vaccine Response in the Immunocompromised Patient with Focus on Cellular Immunity

Guest Editor:

### Dr. Christina Bahrs

1. Institute of Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, 07743 Jena, Germany

2. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, 1090 Vienna, Austria

Deadline for manuscript submissions:

**closed (31 December 2021)**

### Message from the Guest Editor

Dear Colleagues,

The immunocompromised patient has an increased risk of any type of infectious disease, including vaccine-preventable diseases, and often suffers a severe course. Although inactivated vaccines can be safely administered even in severely immunocompromised patients, vaccine rates are particularly low in this vulnerable population. The tailoring of vaccine strategies to the needs of immunosuppressed patients relies on a better understanding of what supports or limits vaccine efficacy. In addition to antibody-mediated protection, cellular immunity is of particular importance, as T cell responses also participate in the reduction, control, and clearance of pathogens. Therefore, articles adding new information on vaccine-induced, cell-mediated immune response in immunocompromised patients are welcome. Adding new information on this subject may lead to a better understanding of the immune response to available vaccines or new vaccine candidates in these particularly vulnerable patients and might help in optimizing vaccine strategies in the future.

Dr. Christina Bahrs

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)